Zilico, which is part of the Deepbridge Life Sciences EIS portfolio, has been awarded £1m in funding to drive technology development for an oral diagnostic device. 
This funding will support Zilico in the development of their Electrical Impedance Spectroscopy technology in the attempt to improve the speed and accuracy of oral pre-cancer and cancer diagnosis. 

For more information please click here. 

By following this link you will leave the Deepbridge website. Deepbridge takes no responsibility for content on external websites.

About Zilico
Zilico Ltd has developed an innovative cancer diagnostic device technology that employs Electrical Impedance Spectroscopy (‘EIS’) within a device that seeks to improve and extend current cancer screening programmes, by providing accurate and objective results in real-time.